CASI Pharmaceuticals (CASI) announced the appointment of Barbara Krebs-Pohl, PhD as an Independent Director to the CASI Board of Directors. Krebs-Pohl is currently the Managing Director of the Foundation for Stem Cell Research and Regenerative Medicine, as well as a Partner and Managing Director at Viopas Venture Consulting, where she advises emerging biotechnology companies on growth and strategic partnerships.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CASI:
- CASI Pharmaceuticals Reports Q2 2025 Results and Strategic Asset Divestiture
- CASI Pharmaceuticals Faces Setback with FOLOTYN® License Expiration in China
- CASI Pharmaceuticals Receives FDA Clearance for CID-103 IND Application
- Casi Pharmaceuticals announces FDA clearance of CID-103 IND application
- CASI Pharmaceuticals Appoints David Cory as CEO to Drive CID-103 Program